• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Zoster-associated Prothrombotic Plasma Exosomes and Increased Stroke Risk
J Infect Dis. 2022 Oct 6:jiac405. doi: 10.1093/infdis/jiac405. Online ahead of print.ABSTRACTHerpes zoster (HZ, shingles) caused by varicella zoster virus (VZV) reactivation increases stroke risk for up to one-year post-HZ. The underlying mechanisms are unclear, however, the development of stroke distant from the site of zoster (e.g. thoracic, lumbar, sacral) that can occur months after resolution of rash points to a long-lasting, virus-induced soluble factor(s) that can trigger thrombosis and/or vasculitis. Herein, we investigated the content and contributions of circulating plasma exosomes from HZ and non-HZ patient samp...
Source: Herpes - October 6, 2022 Category: Infectious Diseases Authors: Andrew N Bubak Christina Coughlan Janelle Posey Anthony J Saviola Christy S Niemeyer Serena W R Lewis Sara Bustos Lopez Adriana Solano Stephen K Tyring Cassidy Delaney Keith B Neeves Ravi Mahalingam Kirk C Hansen Maria A Nagel Source Type: research

Active Post-Licensure Safety Surveillance for Recombinant Zoster Vaccine Using Electronic Health Record Data
Am J Epidemiol. 2022 Oct 4:kwac170. doi: 10.1093/aje/kwac170. Online ahead of print.ABSTRACTRecombinant zoster vaccine (RZV) (Shingrix; GlaxoSmithKline, Brentford, United Kingdom) is an adjuvanted glycoprotein vaccine that was licensed in 2017 to prevent herpes zoster and its complications in older adults. In this prospective, post-licensure Vaccine Safety Datalink (VSD) study using electronic health records, we sequentially monitored a real-world population of adults aged 50 years and older who received care at multiple VSD health systems in the United States to identify potential increased risks of 10 pre-specified prior...
Source: Am J Epidemiol - October 4, 2022 Category: Epidemiology Authors: Jennifer C Nelson Ernesto Ulloa-P érez Onchee Yu Andrea J Cook Michael L Jackson Edward A Belongia Matthew F Daley Rafael Harpaz Elyse O Kharbanda Nicola P Klein Allison L Naleway Hung-Fu Tseng Eric S Weintraub Jonathan Duffy W Katherine Yih Lisa A Jacks Source Type: research

Rare Adverse Events Associated with BNT162b2 mRNA Vaccine (Pfizer-BioNTech): A Review of Large-Scale, Controlled Surveillance Studies
In conclusion, this review has concisely summarized the current rare adverse events related and unrelated to BNT162b2, arguably for the first time in sufficient depth, to better communicate vaccine safety to the public.PMID:35891231 | DOI:10.3390/vaccines10071067
Source: Herpes - July 27, 2022 Category: Infectious Diseases Authors: Shin-Jie Yong Alice Halim Michael Halim Abbas Al Mutair Saad Alhumaid Jehad Al-Sihati Hawra Albayat Mohammed Alsaeed Mohammed Garout Reyouf Al Azmi Noor Aldakheel Abeer N Alshukairi Hani A Al Ali Adel A Almoumen Ali A Rabaan Source Type: research

Increased Stroke Risk Following Herpes Zoster Infection and Protection with Zoster Vaccine
CONCLUSION: Patients had a significantly higher risk of stroke within the first month following recent herpes zoster infection. Receipt of at least one zoster vaccination was found to mitigate this increased risk. Vaccination may therefore be viewed as a protective tool against the risk of neurologic post-infection sequelae.PMID:35796546 | DOI:10.1093/cid/ciac549
Source: Herpes - July 7, 2022 Category: Infectious Diseases Authors: Ganapathi Iyer Parameswaran Bethany A Wattengel Hubert C Chua Jessica Swiderek Tom Fuchs Michael T Carter Laura Goode Kathleen Doyle Kari A Mergenhagen Source Type: research

Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans
CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that there were few differences in risk of adverse events within 14 days of the first dose of either the BNT162b2 or the mRNA-1273 vaccine and small-magnitude differences within 42 days of the first dose. The 38-week risks of adverse events were low in both vaccine groups, although risks were lower for recipients of the mRNA-1273 vaccine than for recipients of the BNT162b2 vaccine. Although the primary analysis was designed to detect safety events unrelated to SARS-CoV-2 infection, the possibility that these differences may partially be explained by a low...
Source: Herpes - June 13, 2022 Category: Infectious Diseases Authors: Barbra A Dickerman Arin L Madenci Hanna Gerlovin Katherine E Kurgansky Jessica K Wise Michael J Figueroa Mu ñiz Brian R Ferolito David R Gagnon J Michael Gaziano Kelly Cho Juan P Casas Miguel A Hern án Source Type: research

Common Features Between Stroke Following Varicella in Children and Stroke Following Herpes Zoster in Adults : Varicella-Zoster Virus in Trigeminal Ganglion
Curr Top Microbiol Immunol. 2021 Jul 6. doi: 10.1007/82_2021_236. Online ahead of print.ABSTRACTThe cerebral arteries are innervated by afferent fibers from the trigeminal ganglia. Varicella-zoster virus (VZV) frequently resides in the trigeminal ganglion. Reports of arterial ischemic stroke due to VZV cerebral vasculopathy in adults after herpes zoster have been described for decades. Reports of arterial ischemic stroke due to post-varicella cerebral arteriopathy in children have also been described for decades. One rationale for this review has been post-licensure studies that have shown an apparent protective effect fro...
Source: Current Topics in Microbiology and Immunology - July 5, 2021 Category: Microbiology Authors: Charles Grose Amir Shaban Heather J Fullerton Source Type: research

Pages: 1  2  3  4  5